Since we first invested in Storm Therapeutics, it has successfully translated world-class science from the University of Cambridge into the leading company tackling disease through modulating RNA modifying enzymes. We are delighted to continue to support the team as it progresses Storm’s programmes further towards the clinic.
Dr Keith Blundy, CEO of Storm Therapeutics said "I am pleased to welcome Seroba to our investor syndicate and I would like to thank our existing investors for their continued support. This investment strengthens our Series A and provides further validation and support for Storm’s strategy to continue building a world-leading company harnessing the power of RNA epigenetics - an emerging, innovative area of drug discovery. It comes at an exciting stage as Storm starts translating its unique platform into effective treatments in oncology and beyond. Mark’s expertise in cancer drug discovery and development, encompassing in vitro and in vivo biology, translational and clinical research, will be invaluable to Storm as it progresses its pipeline towards the clinical stage."